A multi-institution study led by the Prince of Wales Hospital and University of New South Wales, Australia, has found that everolimus-eluting resorbable scaffold treatment leads to better outcomes ...

Results of trials and registry studies have shown lower long-term mortality after coronary-artery bypass grafting (CABG) than after percutaneous coronary intervention (PCI) among patients with ...

Review the side-effects of Everolimus as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Use of the mTOR inhibitor everolimus in the treatment of postmenopausal HR+/HER2– metastatic breast cancer can be hampered by the development of stomatitis/mouth ulcers, which can lead to dose ...

Previous studies have established the superiority of coronary everolimus-eluting stents over paclitaxel-eluting stents with respect to angiographic findings. However, these trials were not powered for ...

Model for Individualized Prediction of Breast Cancer Risk After a Benign Breast Biopsy Patients were considered incurable, had measurable disease, and were treated with up to two prior cytotoxic ...

Post-progression endpoints favored giredestrant/everolimus, reducing second progression or death 31% overall and 39% in ESR1-mutated disease, indicating sustained ...

The immunosuppressant/anticancer agent everolimus was associated with a dramatic reduction in seizures in patients with tuberous sclerosis complex in whom treatment ...

A relevant percentage of patients with metastatic renal cell carcinoma develop intolerance to vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFr-TKIs) and require careful ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of everolimus, having considered evidence on the prevention of organ rejection after a liver transplant, and ...

A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were ...